GlassScriptPhysician profile
Anna Kazaryan
NPI 1689085888
$5,829.78
in general payments reported to CMS, 2019-2025
23 companies · $2,022 in 2025
The $2,022 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.51 · 2022: $933 · 2023: $1,275 · 2024: $1,589 · 2025: $2,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,885.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,511.66 | 2022-2025 | |
| Amgen INC. | $953.15 | 2020-2025 | Tavneos, Evenity, Otezla |
| Glaxosmithkline, LLC. | $585.18 | 2022-2025 | Benlysta |
| Janssen Biotech, INC. | $464.09 | 2022-2025 | Tremfya, Stelara, Remicade |
| Ucb, INC. | $444.90 | 2022-2025 | Cimzia, Bimzelx |
| Aurinia Pharma U.S., INC. | $320.03 | 2022-2025 | Lupkynis |
| Pfizer INC. | $311.15 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $289.49 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $236.05 | 2022-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.95 | 2024-2025 | Ofev |
| Lilly USA, LLC | $137.56 | 2022-2025 | Taltz |
| Ani Pharmaceuticals, INC. | $133.41 | 2022-2024 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $52.49 | 2024-2025 | Orencia |
| Horizon Therapeutics Plc | $46.39 | 2023 | Krystexxa |
| Kiniksa Pharmaceuticals, LTD. | $34.66 | 2022-2023 | Arcalyst |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Invivyd INC | $26.36 | 2025 | Pemgarda |
| Kowa Pharmaceuticals America, INC. | $24.80 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $24.12 | 2024 | Arcalyst |
| Organon LLC | $23.35 | 2024 | |
| Alexion Pharmaceuticals, INC. | $15.61 | 2024 | Strensiq |
| Ultragenyx Pharmaceutical INC. | $15.09 | 2022 | |
| Radius Health, INC. | $14.49 | 2023 | |
| Novo Nordisk INC | $13.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Kazaryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.